eloxatin
sanofi medley farmacÊutica ltda. - oxaliplatina - citostaticos alquilantes
oxa
accord farmacÊutica ltda - oxaliplatina - citostaticos alquilantes
evoxali
farmarin industria e comercio ltda - oxaliplatina - citostaticos alquilantes
liboxal
laboratÓrios libra do brasil ltda - oxaliplatina - citostaticos alquilantes
bioezulen
achÉ laboratÓrios farmacÊuticos s.a - oxaliplatina - citostaticos alquilantes
oxa-platin
blau farmacÊutica s.a. - oxaliplatina - citostaticos alquilantes
oxaliplatina
teva farmacÊutica ltda. - citostaticos alquilantes
collectro
mylan laboratorios ltda - oxaliplatina - citostaticos alquilantes
oxa-platin
blau farmacÊutica s.a. - oxaliplatina - citostaticos alquilantes
teysuno
nordic group b.v. - tegafur, gimeracil, oteracil - neoplasias de estômago - agentes antineoplásicos - teysuno is indicated in adults:- for the treatment of advanced gastric cancer when given in combination with cisplatin (see section 5. - as monotherapy or in combination with oxaliplatin or irinotecan, with or without bevacizumab, for the treatment of patients with metastatic colorectal cancer for whom it is not possible to continue treatment with another fluoropyrimidine due to hand-foot syndrome or cardiovascular toxicity that developed in the adjuvant or metastatic setting.